Stay Ahead with Daily Biotech & HealthTech Innovation Insights
- by O. Rose BroderickHHS appointed 21 new members to a federal committee that advises health secretary RFK Jr. on autism.
- by Brittany TrangHologen, a secretive AI startup co-founded by former Google CEO, is looking to raise $150 million.
- by Associated PressThe government proposed new rules for the nation’s transplant system Wednesday that aim to increase use of less-than-perfect organs and set additional safety standards for donor groups.
- by Bob HermanA tiny pay raise and new restrictions for Medicare Advantage plans show the administration won't go easy on the industry.
- by Megan MolteniGoogle DeepMind announced it was making AlphaGenome’s source code and weights available to the science community for noncommercial use.
- by Brittany TrangIn this edition of AI Prognosis: Brittany Trang takes a closer look at a constellation of health AI validation tools from Stanford researchers.
- by Elaine ChenAnd other biotech news brought to you by The Readout
- by Ed SilvermanThe Trump administration released the next 15 drugs subject to Medicare price negotiation, including for the first time treatments administered in doctor offices
- by Ed SilvermanMore high-income countries have used compulsory licenses to gain access to meds, study finds.
- by Theresa GaffneyAnd other health news from the Morning Rounds newsletter
- by Jason MastFDA paused trials for two experimental gene therapies from Regenxbio after one child developed a brain tumor.
- by Henry I. MillerBeen avoiding the dentist? Would knowing a dog is waiting for you make a difference?
- by Alex HoganHow did gas stations became the perfect marketplace for quasi-legal drugs? STAT's Alex Hogan explains on STATus Report.
- by Brittany TrangSome large health systems are building their own AI-powered chatbots to make it easier for their clinicians to query patients' health records.
- by Barbara Levy and Badrinath KonetyThese physicians are wary of new multi-cancer early detection tests.
- by Jason MastGlioblastoma is almost always fatal. Altido Bio is trying to commercialize a CAR-T cell therapy that has shown rare promise.
- by John WilkersonThe Trump administration released the next 15 drugs subject to Medicare price negotiation, including for the first time treatments administered in doctor offices.
- by Associated PressThe South Carolina measles outbreak has surpassed the recorded case count in Texas' 2025 outbreak, as health officials have logged almost 600 new cases in just over a month.
- by Tara BannowHCA Healthcare put out a 2026 forecast that delighted investors, despite challenges from Medicaid and the ACA.
- by Patrick SmithIn his final moments, Alex Pretti did what nurses are educated to do, a nurse writes. He noticed, cared, and responded to an emergent threat.
- After announcing plans to go public at the top of the year, Eikon Therapeutics has now revealed the proceeds it hopes to pull in from its initial stock offering: $273.5 million.
- As biopharma M&A activity ramps back up, strategy is shifting to no longer focus on securing the next blockbuster drug, but instead to ink deals that build out capabilities across the entire drug development and commercialization process.
- Shortly after acquiring Elektrofi to beef up its subcutaneous drug delivery offerings, Halozyme Therapeutics has struck another deal to purchase Surf Bio.
- The pursuit of animal-sparing research methods is “definitely an evolution and not a revolution,” Charles River’s executive vice president and chief operating officer, Birgit Girshick, said in a recent interview with Fierce. Under a leadership transition unveiled earlier this month, Girshick is set to ascend to the CEO position at the contract research organization in May.
- A brain tumor has prompted the FDA to put clinical holds on two Regenxbio gene therapies, including a candidate that is less than two weeks away from an approval decision. Regenxbio’s share price fell 32% to $9.16 in premarket trading.
- CalciMedica’s stock nosedived after the biotech abandoned a phase 2 study of its calcium release-activated calcium channel inhibitor in patients with acute kidney injury over a “safety concern.”
- Boehringer Ingelheim has shared more phase 2 data on its kidney disease candidate apecotrep, shedding light on the decision to start a pivotal trial of the prospect last week.
- Bain & Company’s new 2026 global M&A report found that medtech dealmaking rebounded last year, with M&A players in 2026 seeking to “outperform the next-best owner” amid softer valuations for assets.
- Eli Lilly is continuing a run of dealmaking to strengthen its genetic medicine offerings by penning a pact with gene editing company Seamless Therapeutics.
- Scientists have discovered a molecule that shrinks brain tumors in mice, raising hopes that the compound could one day become a pill to treat glioblastoma, one of the world’s most pernicious cancers.
- Since launching one year ago with a hearty $300 million series A, Kardigan has been on a biotech speedrun.
- If the pursuit of Metsera signaled Novo Nordisk was ready to pay top dollar for the right innovation, the aftermath has filled Tamara Darsow’s calendar with high-stakes screenings for new opportunities.
- TD Cowen analysts Mathew Blackman and Drew Ranieri have named their top three medtech picks under their evolving “Bones, Bots and No More Shots” portfolio coverage.
- The FDA is freeing Intellia’s CRISPR therapy from one of two clinical holds, allowing a phase 3 study to resume after a grade 4 liver event and subsequent patient death was reported in the sister study.
- Ahead of its acquisition by cancer imaging company Kuva Labs, Lisata Therapeutics has regained the Chinese rights to its lead solid tumor candidate from Qilu Pharmaceutical.
- Four years after listing on the Nasdaq, Genenta Sciences is taking the business in an unexpected direction.
- United Therapeutics’ bioengineered external liver assist system developed to treat patients with acute forms of chronic liver failure proved promising based on early phase 1 trial results.
- Spanish cancer biomarker medtech Reveal Genomics has boosted the roles of three of its founding members.
- Boehringer Ingelheim has penned a 1.05 billion euro ($1.26 billion) biobucks deal for Simcere’s preclinical inflammatory bowel disease (IBD) bispecific antibody.
- Oath Surgical is partnering with tech giant Nvidia to enhance Oath’s AI-powered outpatient surgery center operating system.
- by Frank VinluanThe 15 drugs selected for the Centers for Medicare and Medicaid Services drug price negotiation program accounted for about $27 billion in total prescription spending under Medicare Parts B and D. But this revenue from Medicare makes up a small percentage of each drug manufacturer’s total sales. The post With CMS’s New List of Meds for Drug Price Negotiation, Analyst Sees Small Financial Hit to Pharmas appeared first on MedCity News.
- by Arundhati ParmarThe main question about health bots is accuracy and the trust or distrust that it engenders among users as a result. One journalist from the Washington Post and a strategic advisor to CMS had wildly differing experiences. The post WaPo Columnist and CMS Official Provide Dueling Narratives of ChatGPT Health appeared first on MedCity News.
- by Christopher McSpirittAs RWE continues to influence the future of drug development, pharma companies will inevitably encounter hurdles. But with the right approach, they can be overcome to unlock critical insights and bring better therapies to patients faster. The post Harnessing RWE for Post-Pandemic Healthcare: Accelerating Drug Development with Real-World Data appeared first on MedCity News.
- by Ken PooleAs hospitals adapt to a landscape marked by staffing shortages, financial pressure and escalating safety concerns, security can no longer operate as an afterthought or a cost center. It must be a strategic enabler that protects the workforce, which in turn protects everyone else. The post Rethinking Security Among the Healthcare Workforce Crisis appeared first on MedCity News.
- by Stephanie Baum[Sponsored] A recent webinar sponsored by Overjet offered insights from Affinity Dental Management executives on how AI-driven clinical intelligence software can transform DSOs. The post How One Leading DSO Used Analytics to Drive a 26% Increase in Crown Treatment Planning Rates appeared first on MedCity News.
- by Katie AdamsInvestors at Breyer Capital think 2026 could mark a turning point in digital health, as logistics become as important as scientific innovation. They highlighted three key trends shaping the market: shifting biotech constraints from biology to delivery, bottom-up product adoption by clinicians, and a wave of consolidation among AI startups. The post Which Digital Health Startups Will Win in 2026? appeared first on MedCity News.
- by Frank VinluanPreliminary Phase 2 data show Roche’s CT-388 led to a 22.5% placebo-adjusted weight loss measured at 48 weeks. Based on these results, the pharmaceutical company plans to advance the GLP-1 and GIP agonist to a Phase 3 clinical trial in obesity. The post Roche Obesity Drug’s Phase 2 Results Are Competitive, But True Test May Come From Combo Studies appeared first on MedCity News.
- by Marissa PlesciaThis is Wisp’s first acquisition, for which the terms of the deal were not disclosed. It allows the company to expand into providing in-person care to complement its virtual support. The post Wisp Acquires Sexual Health Platform TBD Health appeared first on MedCity News.
- by lfaubert[Sponsored] Philadelphia’s fitness scene extends beyond basic workouts to support total health and wellness. The post Top Gyms in Philadelphia for Total Health and Wellness appeared first on MedCity News.
- by Dr. Mihir KamdarCaregivers are a backbone of serious illness care, but they cannot carry the system alone. We have reached a point where failing to support them is indistinguishable from failing patients. The post Serious Illness Care Runs on Caregivers — It’s Time to Act Like It appeared first on MedCity News.
- by Michele RagerWe have to cover medical nutrition therapy for those who need it most, including Medicare beneficiaries. Almost all commercial payers are already doing this – the government needs to catch up. The post Medicare Is Covering GLP-1s – It’s Time to Cover the Care That Makes Them Sustainable appeared first on MedCity News.
- by Marissa PlesciaPHTI released a playbook guiding purchasers on how to implement performance-based contracts for digital health solutions, focusing on payment models, outcomes and accountability. The post PHTI: How Purchasers Can Implement Performance-Based Contracting with Digital Health Solutions appeared first on MedCity News.
- by Katie AdamsEndeavor Health is studying Exact Sciences’ Cancerguard blood test to help see if multi-cancer detection should be deployed widely across hospitals. The five-year study aims to fill gaps in real-world evidence on how these tests perform and how they fit into routine healthcare. The post Can Hospitals Use Blood Tests to Catch Cancer Earlier? Endeavor Health Is Trying to Find Out appeared first on MedCity News.
- by Frank VinluanFortitude Biomedicines is developing antibody drug conjugates that use targeted protein degraders as their therapeutic payloads. The startup joins a group of degrader ADC (or DAC) developers that includes Bristol Myers Squibb and Pfizer. The post Startup Fortitude Bio Launches to Beat Drug Resistance in Cancer, Expand ADCs to Autoimmune Disease appeared first on MedCity News.
- by lfaubert[Sponsored] Temperature-sensitive medications represent one of the most critical operational and regulatory challenges in modern pharmacy management. The post Best Automated Systems for Cold Chain Pharmacy Management appeared first on MedCity News.
- by Vikalp KhareFor many organizations, the workload has become too large for manual review alone. AI and automation are stepping in, not to replace the human element, but to restore focus to it. The post The Future of Pharmacovigilance Technology: How AI and Automation Are Redefining Drug Safety appeared first on MedCity News.
- by Daniel GootnerAs individual enrollment grows, agents must evolve to meet a more complex, consumer-driven market. The post Individual Coverage Is Reshaping Health Insurance. Agents Are the Key to Making It Work appeared first on MedCity News.
- by Frank VinluanThe contract research organization consolidation trend continues with Worldwide Clinical Trials striking a deal for Catalyst Clinical Research, which has particular expertise in oncology. Worldwide is a portfolio company of Kohlberg, a private equity firm. The post Worldwide Clinical Trials to Buy Catalyst, Another M&A Deal Between Private Equity-Backed CROs appeared first on MedCity News.
- by Katie AdamsAs OpenAI and Anthropic move deeper into healthcare, experts say AI chatbots are becoming the new front door to medicine. This shift is shaking things up for some health tech startups, redefining the patient-provider relationship, and intensifying debates over safety, privacy and accountability. The post What Does OpenAI and Anthropic’s Healthcare Push Mean for the Industry? appeared first on MedCity News.
- by Marissa PlesciaAnswersNow’s Series B round was led by HealthQuest Capital, with participation from Left Lane Capital and Owl Ventures. The post AnswersNow Raises $40M to Expand Access to Autism Therapy appeared first on MedCity News.
